Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Absci | ABSI | Apr 23, 2024 | 4.71 | +4.43 |
ABVC Biopharma | ABVC | Apr 23, 2024 | 1.35 | +29.81 |
Ac Immune SA | ACIU | Apr 23, 2024 | 2.38 | -1.65 |
Acacia Research | ACTG | Apr 23, 2024 | 4.97 | +0.20 |
Academy Sports and Outdoors | ASO | Apr 23, 2024 | 59.27 | +3.19 |
Acadia Healthcare | ACHC | Apr 23, 2024 | 70.74 | +0.68 |
Acadia Pharmaceuticals | ACAD | Apr 23, 2024 | 16.74 | -1.47 |
Acadia Realty Trust | AKR | Apr 23, 2024 | 17.66 | +1.38 |
Acasti Pharma A | ACST | Apr 23, 2024 | 2.88 | +1.05 |
Accel Entertainment | ACEL | Apr 23, 2024 | 11.68 | +1.04 |
Accelerate Diagnostics | AXDX | Apr 23, 2024 | 0.95 | +7.05 |
Accenture A | ACN | Apr 23, 2024 | 316.83 | -0.19 |
Acco Brands | ACCO | Apr 23, 2024 | 4.98 | +0.40 |
Accolade | ACCD | Apr 23, 2024 | 9.35 | +1.52 |
Accuray | ARAY | Apr 23, 2024 | 2.22 | +2.30 |
Ace Global Business Acquisition | ACBA | Apr 23, 2024 | 12.10 | 0.00 |
Ace Global Business Acquisition Unit | ACBAU | Apr 23, 2024 | 11.96 | 0.00 |
Acelyrin | SLRN | Apr 23, 2024 | 4.60 | -4.56 |
Achieve Life Sciences | ACHV | Apr 23, 2024 | 4.50 | +2.04 |
Achilles Therapeutics ADR | ACHL | Apr 23, 2024 | 0.78 | -1.13 |
ACI Worldwide | ACIW | Apr 23, 2024 | 33.46 | +3.75 |
Aclarion | ACON | Apr 23, 2024 | 0.28 | +2.47 |
Aclaris Therapeutics | ACRS | Apr 23, 2024 | 1.22 | 0.00 |
ACM Research A | ACMR | Apr 23, 2024 | 27.39 | +6.37 |
Acme United | ACU | Apr 23, 2024 | 40.46 | +1.02 |
ACNB | ACNB | Apr 23, 2024 | 34.25 | -1.47 |
Acorda Therapeutics | ACOR | Apr 23, 2024 | 0.88 | 0.00 |
ACRES Commercial Realty | ACR | Apr 23, 2024 | 13.97 | +1.09 |
ACRES Commercial Realty C Pref | ACR-C | Apr 23, 2024 | 23.89 | -0.67 |
ACRES Commercial Realty D Pref | ACR-D | Apr 23, 2024 | 20.80 | -0.34 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.